Our country has never seen anything like COVID-19. The impacts of this crisis on the world are great. That’s why the HudsonAlpha Institute for Biotechnology is doing its part to combat this health crisis. As a global leader in genetics and genomics with an extensive track record in infectious disease, HudsonAlpha is joining the fight against this disease. Your financial support today will help find answers and potential treatments for COVID-19, fund critical equipment demands and provide relief to the Institute’s areas of greatest need. Donate now.
HudsonAlpha President Rick Myers, PhD, explains how HudsonAlpha and resident associate companies are combating the COVID-19 pandemic.
Huntsville Hospital, HudsonAlpha Institute for Biotechnology, and iRepertoire, Inc. are teaming up to study local patients diagnosed with COVID-19 to learn how the immune system responds to the SARS-CoV-2 virus, with hopes for developing an effective treatment for the disease.
Dr. Neil Lamb makes sense of all the information surrounding the coronavirus COVID-19. ‘Beyond the Blog’ gives an easy to understand explanation of the science behind this disease, how it spreads and what scientists are doing to help diagnose and treat the disease.
We’re all about team science at HudsonAlpha — that’s why we collaborate with associate companies on campus to solve global health problems like COVID-19. See what’s happening on campus.
Your gift to HudsonAlpha’s COVID-19 response will advance our efforts to tackle this devastating coronavirus/disease. By teaming with HudsonAlpha, you will directly support:Â
- Research to better understand COVID-19
- Projects that may lead to potential treatment development
- Resources, including supplies, equipment and technology to keep HudsonAlpha up and running during this critical time
- Educational updates and programs
When you give, you will fuel research to understand and treat COVID-19 and help support the impact to HudsonAlpha during this time. Thank you for joining the fight against the coronavirus pandemic. Give today.